Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference.

Launay, M; Guitton, J; Balluet, R; Moreau, A; Phelip, J-M; Tholance, Y; Gonzalo, P

Launay, M; Guitton, J; Balluet, R; Moreau, A; Phelip, J-M; Tholance, Y; Gonzalo, P.

Afiliação

Launay M; Laboratory of Pharmacology, Toxicology and Blood Gazes, University Hospital of Saint Etienne, Saint Etienne. Electronic address: manon.launay@chu-st-etienne.fr.
Guitton J; Laboratory of Pharmacology and Toxicology, Lyon-Sud University Hospital-Hospices Civil de Lyon, Lyon.
Balluet R; Laboratory of Pharmacology, Toxicology and Blood Gazes, University Hospital of Saint Etienne, Saint Etienne.
Moreau A; Laboratory of Biochemistry, University Hospital of Saint Etienne, Saint Etienne.
Phelip JM; Department of Gastroenterology and Digestive Oncology, University Hospital of Saint Etienne, Saint Etienne, France.
Tholance Y; Laboratory of Biochemistry, University Hospital of Saint Etienne, Saint Etienne.
Gonzalo P; Laboratory of Biochemistry, University Hospital of Saint Etienne, Saint Etienne.

Ann Oncol ; 33(8): 850-852, 2022 08.

Article em En | MEDLINE | ID: mdl-35525375

Assuntos

Deficiência da Di-Hidropirimidina Desidrogenase; Neoplasias; Síndrome de Lise Tumoral; Di-Hidrouracila Desidrogenase (NADP); Fluoruracila; Humanos; Neoplasias/complicações; Neoplasias/diagnóstico; Síndrome de Lise Tumoral/diagnóstico; Síndrome de Lise Tumoral/etiologia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome de Lise Tumoral / Deficiência da Di-Hidropirimidina Desidrogenase / Neoplasias Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google